UY36617A - Proteínas de fusión inmunogénicas para el tratamiento del cáncer - Google Patents

Proteínas de fusión inmunogénicas para el tratamiento del cáncer

Info

Publication number
UY36617A
UY36617A UY0001036617A UY36617A UY36617A UY 36617 A UY36617 A UY 36617A UY 0001036617 A UY0001036617 A UY 0001036617A UY 36617 A UY36617 A UY 36617A UY 36617 A UY36617 A UY 36617A
Authority
UY
Uruguay
Prior art keywords
fusion proteins
cancer treatment
immunogenic fusion
triggering
methods
Prior art date
Application number
UY0001036617A
Other languages
English (en)
Inventor
Peter M Lauer
William G Hanson
Dirk G Brockstedt
Meredith Lai Ling Leong
Fasso Marcella
Christopher Steven Rae
Charles G Drake
Original Assignee
Aduro Biotech Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc, Univ Johns Hopkins filed Critical Aduro Biotech Inc
Publication of UY36617A publication Critical patent/UY36617A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan composiciones y métodos para desencadenar una respuesta inmunitaria en un sujeto. En particular, la presente divulgación se dirige a proteínas de fusión inmunogénicas y a métodos para desencadenar una respuesta inmunitaria usando células hospedadoras que comprenden moléculas de ácido nucleico que codifican dichas proteínas de fusión.
UY0001036617A 2015-04-13 2016-04-12 Proteínas de fusión inmunogénicas para el tratamiento del cáncer UY36617A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562146654P 2015-04-13 2015-04-13
US201562146626P 2015-04-13 2015-04-13
US201562263174P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
UY36617A true UY36617A (es) 2016-10-31

Family

ID=55808893

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036617A UY36617A (es) 2015-04-13 2016-04-12 Proteínas de fusión inmunogénicas para el tratamiento del cáncer

Country Status (11)

Country Link
US (2) US9808516B2 (es)
EP (1) EP3283100A2 (es)
JP (1) JP2018512165A (es)
CN (1) CN107980044A (es)
AU (1) AU2016247894A1 (es)
CA (1) CA2982543A1 (es)
HK (2) HK1250731A1 (es)
MA (1) MA44378A (es)
TW (1) TW201704267A (es)
UY (1) UY36617A (es)
WO (1) WO2016168214A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
UY36616A (es) 2015-04-13 2016-10-31 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
JP2018512165A (ja) 2015-04-13 2018-05-17 アデュロ バイオテック，インコーポレイテッド 癌の治療のための免疫原性融合タンパク質
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CN118290563B (zh) * 2024-06-03 2024-08-02 磐如生物科技(天津)有限公司 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
WO2001072329A1 (en) 2000-03-29 2001-10-04 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
CA2206343C (en) 1994-11-28 2009-04-07 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
EP1575500A4 (en) 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINE AND MODEL SYSTEMS
JP2006514823A (ja) 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
AU2004249254B2 (en) 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
WO2007103225A2 (en) 2006-03-01 2007-09-13 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
RS57630B1 (sr) 2010-11-17 2018-11-30 Aduro Biotech Inc Metode i sastavi za uzrokovanje imunog odgovora na egfrviii
WO2012141984A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2014106123A1 (en) * 2012-12-27 2014-07-03 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
CN104211814A (zh) 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
UY36616A (es) 2015-04-13 2016-10-31 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
JP2018512165A (ja) 2015-04-13 2018-05-17 アデュロ バイオテック，インコーポレイテッド 癌の治療のための免疫原性融合タンパク質

Also Published As

Publication number Publication date
US20160324945A1 (en) 2016-11-10
TW201704267A (zh) 2017-02-01
US9808516B2 (en) 2017-11-07
AU2016247894A1 (en) 2017-10-26
EP3283100A2 (en) 2018-02-21
CN107980044A (zh) 2018-05-01
US20180085446A1 (en) 2018-03-29
MA44378A (fr) 2019-01-23
CA2982543A1 (en) 2016-10-20
HK1250662A1 (zh) 2019-01-11
JP2018512165A (ja) 2018-05-17
WO2016168214A3 (en) 2016-12-22
WO2016168214A2 (en) 2016-10-20
HK1250731A1 (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
AR118725A2 (es) Vectores para expresión de antígenos asociados a próstata
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CL2017002728A1 (es) Método para el tratamiento de cáncer
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
MX2018007627A (es) Vacuna contra el virus del zika.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
MX2016015952A (es) Constructos de anticuerpo multiespecifico.
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
AR102527A1 (es) Vacunas terapéuticas para hpv16
MX2016002166A (es) Anticuerpos.
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
MX2023006415A (es) Anticuerpos, usos y metodos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104